aln app (Alnylam Inc)
86
Structured Review
Alnylam Inc
aln app
Aln App, supplied by Alnylam Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aln+app/aln+app/pmc12908064-380-8-14
Average 86 stars, based on 1 article reviews
Aln App, supplied by Alnylam Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aln+app/aln+app/pmc12908064-380-8-14
Average 86 stars, based on 1 article reviews
aln app - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
other:Article Title: Targeting Amyloid-β Proteins as Potential Alzheimer’s Disease Therapeutics: Anti-Amyloid Drug Discovery, Emerging Therapeutics, Clinical Trials and Implications for Public Health Article Snippet: ALN-APP , Disease modifying biological agent , Aβ , RNAi to reduce APP and down-stream Aβ related events , Phase-1 , NCT05231785 , Feb-2022 , Article Title: Recent Progress of Small Interfering RNA Delivery on the Market and Clinical Stage. Article Snippet: Small interfering RNAs (siRNAs) are promising therapeutic strategies, and five siRNA drugs have been approved by the Food and Drug Administration (FDA) and the European Commission (EC).. This marks a significant milestone in the development of siRNA for clinical applications.. The approved siRNA agents can effectively deliver siRNAs to the liver and treat liver-related diseases. Article Title: SCAD: A modular platform for efficient delivery of duplex RNA to the CNS and beyond Article Snippet: For example, ALN-APP was the first Article Title: The landscape of nanoparticle-based siRNA delivery and therapeutic development Article Snippet: ALN-APP , NA , PS, 2′-OMe, 2′-F , intrathecal , cerebral amyloid angiopathy , Conjugation Assay:Article Title: Overcoming the blood‒brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer's disease Article Snippet: .. Transformation Assay:Article Title: Brain-targeted delivery of siRNA via non-viral delivery systems, the therapeutic strategy for Alzheimer's disease—Unveiling challenges and prospects Article Snippet: .. Early results from this phase I trial of ALN-APP ( NCT05231785 ) demonstrate that |